Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisJulie B. Dumond, Angela D. M. Kashuba, Rosa F. Yeh et al.|AIDS|2007Cited by 178
Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative WomenJulie B. Dumond, Angela D. M. Kashuba, Kristine B. Patterson et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2009Cited by 127
Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative MenKevin C. Brown, Angela D. M. Kashuba, Kristine B. Patterson et al.|The Journal of Infectious Diseases|2011Cited by 86
Pre-exposure prophylaxis for HIV prevention: how to predict successAngela D. M. Kashuba, Myron S. Cohen, Kristine B. Patterson et al.|The Lancet|2011Cited by 73
A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/RitonavirJulie B. Dumond, Angela D. M. Kashuba, Nicole White et al.|Clinical Pharmacology & Therapeutics|2010Cited by 63